Product Data Sheet

Resminostat (RAS2410)



Cat. No.:	A4108
CAS No.:	864814-88-0
Formula:	C16H19N3O4S
M.Wt:	349.4
Synonyms:	
Target:	DNA Damage/DNA Repair
Pathway:	HDAC
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

Soluble in DMSO

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.8620 mL	14.3102 mL	28.6205 mL
5 mM	0.5724 mL	2.8620 mL	5.7241 mL
10 mM	0.2862 mL	1.4310 mL	2.8620 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Potent HDAC inhibitor
IC_{50} & Target	

In Vitro

Cell Viability Assay

Cell Line:	OPM-2, NCI-H929, RPMI-8226 and U266 cell lines
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	5 μmol/L and 10 μmol/l; 4, 24, 48, 72 and 96 h
Applications:	In U266 cells, Resminostat (RAS2410) led to histone hyper-acetylation. In

		human MM cell lines OPM-2, NCI-H929, RPMI-8226 and U266 cell lines, Resminostat (10 μmol/l) induced apoptosis by 73%, 93%, 82% and 46%, respectively. Resminostat also strongly inhibited myeloma cell proliferation up to 92%.
In Vivo	**Animal experiment**	
	Dosage form:	once-daily on days 1-5 every 14 days at 5 dose levels between 100 mg and 800 mg; administered orally
	Applications:	Nineteen patients with advanced solid tumors were treated with Resminostat. At 800 mg, 1 patient experienced grade 3 nausea and vomiting, grade 2 liver enzyme elevation, and grade 1 hypokalemia and thrombocytopenia; which were combined dose-limiting toxicities (DLTs). Pharmacodynamic inhibition of HDAC enzyme was dose-dependent and reached 100% at doses ≥400 mg. Eleven heavily pre-treated patients had stable disease and 1 patient with metastatic thymoma had a 27% reduction in target lesion dimensions.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1.Bagnall NH, Hines BM, et al."Insecticidal activities of histone deacetylase inhibitors against a dipteranparasite of sheep, Lucilia cuprina." Int J Parasitol Drugs Drug Resist. 2017Apr;7(1):51-60.PMID:28110187

See more customer validations on www.apexbt.com.

References

[1]. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol. 2010; 149(4):518-528.

[2] Brunetto AT1, Ang JE, Lal R, et al. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2013 Oct 1;19(19):5494-504.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com